Mylan Inc will be forced to divest injectable generic drugs before it can complete a proposed $1.85 billion acquisition of Agila Specialities Global Pte Ltd and Agila Specialties Pvt Ltd after the US Federal Trade Commission (FTC) applied conditions to the deal.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
FTC, Mylan, Agila, antitrust, acquisition